Navigation Links
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
Date:12/14/2008

n Cancer Center and Professor of Medicine & Women's Health at the Albert Einstein College of Medicine in New York, and lead investigator on the study. "The study suggests that the combination of DOXIL and docetaxel may be an effective treatment for patients with metastatic breast cancer who have relapsed after prior adjuvant anthracycline therapy."

Study Background

The study enrolled 751 women in 19 countries. Patients were randomly assigned to one of two treatment arms: DOXIL 30 mg/m2 followed by docetaxel 60 mg/m2 on the first day of every 21-day cycle; or docetaxel 75 mg/m2 on the first day of every 21-day cycle. Treatment continued until an unacceptable treatment-related toxicity or disease progression occurred.

The primary endpoint of the study was time to progression, as determined by independent reviewers blinded to study treatment. Secondary endpoints included response rate, overall survival and safety.

Response rates (the percentage of patients whose cancer shrinks after treatment) in patients treated with the DOXIL and docetaxel combination were significantly higher than those treated with docetaxel monotherapy (35% versus 26% respectively; p= 0.0085). Overall survival data were not yet mature; a final protocol-specified survival analysis is planned after the occurrence of 485 events.

The most common adverse reactions (e.g., those occurring in at least 20% of the patients) for the DOXIL and docetaxel combination compared to the monotherapy group, respectively, were:

     * Hematological toxicities and infections, including:
         - Neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with
           febrile neutropenia reported in 7% versus 6% of patients
         - Anemia - 20% (Grade 3/4 2%) versus 17% (Grade 3/4 1%)
         - Infection - 30% (Grade 3/4 5%) versus 25% (Grade 3/4 2%)
     * Hand-foot syndrome:  61% (Grade 3/4 24%
'/>"/>
SOURCE  Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 

Related medicine technology :

1. Major deCODE-led Study Underscores Role of the Brain in Obesity
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
4. Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients With Serious Psychotropic Side Effects
5. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
6. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
7. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
8. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
9. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
10. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Calif. , May 16, 2013 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies for ... Richard King , President and CEO, will ... at the Sheraton New York Hotel in New ... May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT. ...
(Date:5/16/2013)... , May 16, 2013  ULURU Inc. (OTCQB: ULUR) ... March 31, 2013 and provided a review of its operating ... Company is confirming the previously communicated outlook for 2013: ... , Expanding the network of distribution partners to cover all ... , Positioning Altrazeal ® to be marketed in approximately ...
(Date:5/16/2013)... , May 16, 2013  A new survey of ... with vulvar and vaginal atrophy (VVA) are either unaware ... are simply dissatisfied with the therapies available. The REVIVE ... VI ews of Treatment Options for Menopausal Vulvar/ ... the treatment of VVA, including lack of knowledge, reluctance ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3ULURU Inc. Reports First Quarter 2013 Financial Results 2ULURU Inc. Reports First Quarter 2013 Financial Results 3ULURU Inc. Reports First Quarter 2013 Financial Results 4ULURU Inc. Reports First Quarter 2013 Financial Results 5New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy 2New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy 3
... Dec. 16 Cohera Medical Inc. today announced the ... its lead surgical adhesive product, TissuGlu®. Initiation of the ... of the lead product toward clinical practice. , ... to investigate the safety of TissuGlu and its effect ...
... , , HARTFORD, Conn., ... leading provider of home health benefits management services, announced ... from URAC, a Washington, DC-based health care accrediting organization ... URAC standards guarantee that only appropriately trained, qualified clinical ...
Cached Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3CareCentrix Receives URAC Health Utilization Management Accreditation 2
(Date:5/18/2013)... 18, 2013 Scott Tischler of Tischler Brothers ... These five keys to losing weight played a huge part ... of Scott Tischler, Troy was able to lose a pound ... loss program should be approached with caution and any activity ... the five keys to weight loss that Scott Tischler advocates. ...
(Date:5/18/2013)... May 18, 2013 Wine World Accessories, ... offering its customers an attractive 25% discount on Franmara ... , Customers can now purchase this electric corkscrew opener ... online transactional process. The online store ensures delivery of ... of order placement. , A spokesperson from the ...
(Date:5/18/2013)... the the Stevens Johnson Syndrome Foundation, Stevens Johnson Syndrome (SJS), ... reaction usually to medicine (i). The first signs of ... blistering and large areas of dead skin. Some severe ... any time and seriously affect both children and adults. ... after he received kidney medicine which caused SJS (ii). ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Three new ... two health and wellness centers and one therapeutic dispensary. ... three locations, the weekend of May 25th – May ... celebrating Memorial Day. All events will take ... May 25th , Elements Therapeutic Dispensary , 10580 S. ...
(Date:5/17/2013)... 2013 Orriant is flexing its ... to businesses across the U.S. with an enhanced ... rigorous infrastructure upgrades for their telecommunications platform, which ... via voice and data. As a company ... healthcare costs and take advantage of federal ...
Breaking Medicine News(10 mins):Health News:Now Save 25% on Franmara Dynamo Electric Wine Bottle Opener at Wine World Accessories 2Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:Elements Honors Medical Marijuana Patients at Elements Health and Wellness Centers and Elements Therapeutic Dispensary 2Health News:Elements Honors Medical Marijuana Patients at Elements Health and Wellness Centers and Elements Therapeutic Dispensary 3Health News:Elements Honors Medical Marijuana Patients at Elements Health and Wellness Centers and Elements Therapeutic Dispensary 4Health News:New Telecommunications Upgrade Provides More Capacity for National Corporate Wellness Programs offered by Orriant 2
... may have a way to make the powerful cancer drug ... some cancers. The chemotherapeutic agent used in combination with other ... or failure in about 30 percent of users, although the ... to protect the kidneys is advise patients to drink more ...
... News) -- A man,s heart disease risk after the age of ... body size and placenta size when he was born, a new ... lifetime nutrition and the early growth of her child," study lead ... University of Southampton in the United Kingdom, said in a news ...
... study published in the journal Clinical Cardiology ... resynchronization therapy (CRT) improves patients, libido, erectile dysfunction, and ... complex clinical syndrome characterized by fatigue and exercise intolerance. ... CRT, which is a type of pacemaker that paces ...
... Physicians can help their patients follow prescribed ... chronic disease management by using a three-pronged ... the University of California, Riverside, Texas State University-San ... The Information-Motivation-Strategy (IMS) Model developed after ...
... at the University of Southern California have pinned down ... survival trait: our ability to comprehend a sceneeven one ... The key is to process the interacting objects ... according to corresponding author Irving Biederman, professor of psychology ...
... hurdles in obtaining an appointment for care with an ... of Medicine at the University of Pennnsylvania that will ... meeting of American Society of Clinical Oncology (Abstract #6128). ... an appointment, with just 22 percent of them obtaining ...
Cached Medicine News:Health News:Cause and potential treatment found for cancer drug's kidney toxicity 2Health News:Male Heart Disease May Be Linked to Mom's Lifetime Nutrition 2Health News:Researchers develop strategy to improve patient adherence 2Health News:Researchers develop strategy to improve patient adherence 3Health News:USC study locates the source of key brain function 2Health News:Two-thirds of newly diagnosed cancer patients unable to obtain oncology appointments 2
... Includes PowerPac 200 power ... Range of Parameters. Quantitative Transfers. ... or Overnight Transfers. Faster, ... High Field-Intensity Transfers with ...
The Trans-Blot transfer cell, used with the included PowerPac 200 power supply, performs efficient, high-intensity electrophoretic transfers. The Trans-Blot cell offers many advantages....
... running Criterion precast gels and Criterion ... fit for use with the incredible ... Criterion blotter combines excellent blotting efficiency ... system and the ease-of-use of the ...
... SD semi-dry transfer cell allows ... Using a platinum-coated titanium plate ... stainless steel plate as the ... transfers in a horizontal configuration ...
Medicine Products: